3:12 PM
 | 
Sep 15, 2017
 |  BioCentury  |  Finance

Orphan opportunity

Why KKR returned to co-lead Orphan play BridgeBio's $135M round

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years.

KKR co-led the Sept. 13 round with new investor Viking Global Investors. Other new investors included AIG, Aisling Capital, Cormorant Capital and Janus Funds. Existing investor Perceptive Advisors also participated.

Unlike KKR’s other biopharma portfolio companies, BridgeBio is...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >